Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 206

1.

Peptide-loaded Langerhans cells, despite increased IL15 secretion and T-cell activation in vitro, elicit antitumor T-cell responses comparable to peptide-loaded monocyte-derived dendritic cells in vivo.

Romano E, Rossi M, Ratzinger G, de Cos MA, Chung DJ, Panageas KS, Wolchok JD, Houghton AN, Chapman PB, Heller G, Yuan J, Young JW.

Clin Cancer Res. 2011 Apr 1;17(7):1984-97. doi: 10.1158/1078-0432.CCR-10-3421. Epub 2011 Feb 25. Erratum in: Clin Cancer Res. 2011 Jun 1;17(11):3851. Wolchock, Jedd D [corrected to Wolchok, Jedd D].

PMID:
21355077
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.

Palucka AK, Ueno H, Connolly J, Kerneis-Norvell F, Blanck JP, Johnston DA, Fay J, Banchereau J.

J Immunother. 2006 Sep-Oct;29(5):545-57.

PMID:
16971810
[PubMed - indexed for MEDLINE]
3.

IL-15-induced human DC efficiently prime melanoma-specific naive CD8+ T cells to differentiate into CTL.

Dubsky P, Saito H, Leogier M, Dantin C, Connolly JE, Banchereau J, Palucka AK.

Eur J Immunol. 2007 Jun;37(6):1678-90.

PMID:
17492620
[PubMed - indexed for MEDLINE]
4.

Melanoma-reactive class I-restricted cytotoxic T cell clones are stimulated by dendritic cells loaded with synthetic peptides, but fail to respond to dendritic cells pulsed with melanoma-derived heat shock proteins in vitro.

Fleischer K, Schmidt B, Kastenmüller W, Busch DH, Drexler I, Sutter G, Heike M, Peschel C, Bernhard H.

J Immunol. 2004 Jan 1;172(1):162-9.

PMID:
14688322
[PubMed - indexed for MEDLINE]
Free Article
5.

Novel approach to the characterization of melanoma associated-peptide-specific CTL lines from Japanese metastatic melanoma patients.

Akiyama Y, Maruyama K, Tai S, Takikawa M, Ohshita C, Yamamoto A, Yamazaki N, Kiyohara Y, Yamaguchi K.

Int J Oncol. 2008 Sep;33(3):433-41.

PMID:
18695871
[PubMed - indexed for MEDLINE]
6.

Tumor cell lysate-pulsed human dendritic cells induce a T-cell response against pancreatic carcinoma cells: an in vitro model for the assessment of tumor vaccines.

Schnurr M, Galambos P, Scholz C, Then F, Dauer M, Endres S, Eigler A.

Cancer Res. 2001 Sep 1;61(17):6445-50.

PMID:
11522639
[PubMed - indexed for MEDLINE]
Free Article
7.

Analysis and characterization of antitumor T-cell response after administration of dendritic cells loaded with allogeneic tumor lysate to metastatic melanoma patients.

Bercovici N, Haicheur N, Massicard S, Vernel-Pauillac F, Adotevi O, Landais D, Gorin I, Robert C, Prince HM, Grob JJ, Leccia MT, Lesimple T, Wijdenes J, Bartholeyns J, Fridman WH, Salcedo M, Ferries E, Tartour E.

J Immunother. 2008 Jan;31(1):101-12.

PMID:
18157017
[PubMed - indexed for MEDLINE]
8.

Intralymphatic dendritic cell vaccination induces tumor antigen-specific, skin-homing T lymphocytes.

Grover A, Kim GJ, Lizée G, Tschoi M, Wang G, Wunderlich JR, Rosenberg SA, Hwang ST, Hwu P.

Clin Cancer Res. 2006 Oct 1;12(19):5801-8.

PMID:
17020987
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Route of administration modulates the induction of dendritic cell vaccine-induced antigen-specific T cells in advanced melanoma patients.

Lesterhuis WJ, de Vries IJ, Schreibelt G, Lambeck AJ, Aarntzen EH, Jacobs JF, Scharenborg NM, van de Rakt MW, de Boer AJ, Croockewit S, van Rossum MM, Mus R, Oyen WJ, Boerman OC, Lucas S, Adema GJ, Punt CJ, Figdor CG.

Clin Cancer Res. 2011 Sep 1;17(17):5725-35. doi: 10.1158/1078-0432.CCR-11-1261. Epub 2011 Jul 19.

PMID:
21771874
[PubMed - indexed for MEDLINE]
Free Article
10.

Human Langerhans cells use an IL-15R-α/IL-15/pSTAT5-dependent mechanism to break T-cell tolerance against the self-differentiation tumor antigen WT1.

Romano E, Cotari JW, Barreira da Silva R, Betts BC, Chung DJ, Avogadri F, Fink MJ, St Angelo ET, Mehrara B, Heller G, Münz C, Altan-Bonnet G, Young JW.

Blood. 2012 May 31;119(22):5182-90. doi: 10.1182/blood-2011-09-382200. Epub 2012 Apr 17.

PMID:
22510877
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients.

de Vries IJ, Lesterhuis WJ, Scharenborg NM, Engelen LP, Ruiter DJ, Gerritsen MJ, Croockewit S, Britten CM, Torensma R, Adema GJ, Figdor CG, Punt CJ.

Clin Cancer Res. 2003 Nov 1;9(14):5091-100.

PMID:
14613986
[PubMed - indexed for MEDLINE]
Free Article
12.

Dendritic cells, pulsed with lysate of allogeneic tumor cells, are capable of stimulating MHC-restricted antigen-specific antitumor T cells.

Mahdian R, Kokhaei P, Najar HM, Derkow K, Choudhury A, Mellstedt H.

Med Oncol. 2006;23(2):273-82.

PMID:
16720928
[PubMed - indexed for MEDLINE]
13.

Wild-type and modified gp100 peptide-pulsed dendritic cell vaccination of advanced melanoma patients can lead to long-term clinical responses independent of the peptide used.

Lesterhuis WJ, Schreibelt G, Scharenborg NM, Brouwer HM, Gerritsen MJ, Croockewit S, Coulie PG, Torensma R, Adema GJ, Figdor CG, de Vries IJ, Punt CJ.

Cancer Immunol Immunother. 2011 Feb;60(2):249-60. doi: 10.1007/s00262-010-0942-x. Epub 2010 Nov 11.

PMID:
21069321
[PubMed - indexed for MEDLINE]
14.

Targeting CD4(+) T-helper cells improves the induction of antitumor responses in dendritic cell-based vaccination.

Aarntzen EH, De Vries IJ, Lesterhuis WJ, Schuurhuis D, Jacobs JF, Bol K, Schreibelt G, Mus R, De Wilt JH, Haanen JB, Schadendorf D, Croockewit A, Blokx WA, Van Rossum MM, Kwok WW, Adema GJ, Punt CJ, Figdor CG.

Cancer Res. 2013 Jan 1;73(1):19-29. doi: 10.1158/0008-5472.CAN-12-1127. Epub 2012 Oct 18.

PMID:
23087058
[PubMed - indexed for MEDLINE]
Free Article
15.

Characterization of MHC class-I restricted TCRalphabeta+ CD4- CD8- double negative T cells recognizing the gp100 antigen from a melanoma patient after gp100 vaccination.

Voelkl S, Moore TV, Rehli M, Nishimura MI, Mackensen A, Fischer K.

Cancer Immunol Immunother. 2009 May;58(5):709-18. doi: 10.1007/s00262-008-0593-3. Epub 2008 Oct 3.

PMID:
18836718
[PubMed - indexed for MEDLINE]
Free PMC Article
16.
17.

Autologous human monocyte-derived dendritic cells genetically modified to express melanoma antigens elicit primary cytotoxic T cell responses in vitro: enhancement by cotransfection of genes encoding the Th1-biasing cytokines IL-12 and IFN-alpha.

Tüting T, Wilson CC, Martin DM, Kasamon YL, Rowles J, Ma DI, Slingluff CL Jr, Wagner SN, van der Bruggen P, Baar J, Lotze MT, Storkus WJ.

J Immunol. 1998 Feb 1;160(3):1139-47.

PMID:
9570527
[PubMed - indexed for MEDLINE]
Free Article
18.

Langerhans cells derived from genetically modified human CD34+ hemopoietic progenitors are more potent than peptide-pulsed Langerhans cells for inducing antigen-specific CD8+ cytolytic T lymphocyte responses.

Yuan J, Latouche JB, Reagan JL, Heller G, Riviere I, Sadelain M, Young JW.

J Immunol. 2005 Jan 15;174(2):758-66.

PMID:
15634896
[PubMed - indexed for MEDLINE]
Free Article
19.

gp100(209-2M) peptide immunization of human lymphocyte antigen-A2+ stage I-III melanoma patients induces significant increase in antigen-specific effector and long-term memory CD8+ T cells.

Walker EB, Haley D, Miller W, Floyd K, Wisner KP, Sanjuan N, Maecker H, Romero P, Hu HM, Alvord WG, Smith JW 2nd, Fox BA, Urba WJ.

Clin Cancer Res. 2004 Jan 15;10(2):668-80.

PMID:
14760090
[PubMed - indexed for MEDLINE]
Free Article
20.

Dendritic cell immunizations alone or combined with low doses of interleukin-2 induce specific immune responses in melanoma patients.

Escobar A, López M, Serrano A, Ramirez M, Pérez C, Aguirre A, González R, Alfaro J, Larrondo M, Fodor M, Ferrada C, Salazar-Onfray F.

Clin Exp Immunol. 2005 Dec;142(3):555-68.

PMID:
16297169
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk